Immuron Announces Positive Results of IMM-124E in Acute Colitis Research Program

Immuron Announces Positive Results of IMM-124E in Acute Colitis Research Program
Australia's Immuron announced beneficial results of IMM-124E in acute models of colitis, including clinical parameters, tissue analysis, and immunological biomarkers. Colitis refers mainly to ulcerative colitis and Crohn's disease, major categories of inflammatory bowel disease that affect millions of people worldwide. Current knowledge indicates that colitis results from complex interactions between the environment, genetic predisposition, immune response and the gut microbiome. The disease can cause many symptoms, such as abdominal pain, fever, weight loss, fatigue, and chronic diarrhea, leading to severe limitations in the patient’s quality of life. Current treatment is not completely successful in up to one-third of patients with colitis and can cause side effects and complications. Also, even in cases where removal of the colon (a colectomy) is performed, certain symptoms of colitis may persist after surgery. Immuron’s IMM-124E was designed to have strong neutralizing activity against lipopolysaccharides (LPS) antigens, which trigger a pro-inflammatory response. Therefore, IMM-124E would decrease the activity of pro-inflammatory T-cells (immune cells) associated with chronic inflammation. This effect of IMM-124E would be strengthened by adjuvant treatments that promote regulatory T-cells and suppress inflammation in target organs. The study’s results mark the completion of the first stage of Immuron’s colitis preclinical program. The study was performed in collaboration with a research team led by Gerhard Rogler, MD, PhD, at the University of Zurich in Switzerland. The scientists designed a three-stage preclinical research program to evaluate IMM-124E in well-established animal models of colitis. “
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *